We currently have multiple research studies available.
Alzheimer's Disease and Cerebral Blood Flow
We are working with a pharmaceutical company that is developing a new device hypothesized to increase cerebral blood flow. This, in turn, is thought to help improve cognition in people with mild Alzheimer's disease.
Alzheimers Disease and Behavior Changes
What's alzheimer's disease? Although Alzheimer's disease is known for memory loss or memory impairment, many patients become easily upset or irritable and their personalities may change. This can be difficult for the patient as well as their family and caregivers.
Studies are being done to evaluate if new medications may improve this aspect of Alzheimer's disease. The Northwest Clinical Research Center has the opportunity to evaluate if medication may help in management.
Symptoms of Alzheimer's That May Predispose Someone to Behavioral or Personality Changes
- Increased memory loss and confusion
- Problems recognizing family and friends
- Problems coping with new situations
- Hallucinations, delusions, and paranoia
- Difficulty completing tasks (complex tasks such as driving, shopping, or finances or activities of daily living such as getting dressed, bathing, toileting, or eating)
The Role of a Caregiver
For all of our studies for dementia, a study partner or caregiver is required. The role of a caregiver is vital for evaluating the study medication. They will be attending visits and communicating with study personnel to help the study team monitor symptoms such as memory impairment, functioning at home, and behavior. Without research volunteers and their family and friends, it would not be possible to evaluate if these new treatments for Alzheimer’s dementia maintain functioning as well as the quality of life for patients and caregivers. Compensation for your time and a travel stipend are available to those who qualify and elect to participate.
Clinical Study Participation
Northwest Clinical Research Center is conducting multiple clinical research studies evaluating treatments to monitor memory and behavior in adults between the ages of 55 up to 90 with Alzheimer's disease.
No Cost Study
There is no cost to participate in the study. If they qualify for the study, the participant will receive the following:
- Medical evaluation.
- Investigational Medication or Device.
- Study Related Medical Care.
- Compensation up to $1,800.
- Complimentary transportation or a travel stipend.